• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Renovorx Inc (NQ: RNXT )

    1.075 +0.035 (+3.37%)
    Streaming Delayed Price Updated: 2:32 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Renovorx Inc

    < Previous 1 2 3 4 5 6 7 Next >
    RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
    From RenovoRx, Inc.
    Via Business Wire
    Biopharma Company Issues New Patent Application Adding to Strong IP Portfolio of 9 Patents Issued and 9 Pending; Phase 3 Clinical Trials for Cancer Treatments in Collaboration with Imugene: RenovoRx (NASDAQ: RNXT) $RNXT
    Via Viz Release
    Topics Intellectual Property
    Exposures Intellectual Property
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Recap: RenovoRx Q3 Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
    From RenovoRx, Inc.
    Via Business Wire
    Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
    Via Get News
    Topics Intellectual Property
    Exposures Intellectual Property
    RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
    From RenovoRx, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
    Via Get News
    RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
    --News Direct-- 
    Via News Direct
    RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
    Via TheNewswire.com
    RenovoRx, Inc. Stock Presents A Compelling Value Proposition After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
    Via AB Newswire
    Topics Death
    Exposures Death
    RenovoRx, Inc. Stock Surges After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
    Via AB Newswire
    Topics Death
    Exposures Death
    Why RenovoRx Stock Is Moving Today
    RenovoRx, Inc. (NASDAQ: RNXT) shares are trading higher Thursday after the company released interim data on progression-free survival from Phase 3 open label TIGeR-PaC study of RenovoGem 
    Via Benzinga
    Microcap Biotech Stock RenovoRx is Shooting Higher Today: Here's Why
    RenovoRx Inc (NASDAQ: RNXT) presented new data on progression-free survival (PFS) from the pivotal Phase 3 open-label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in... 
    Via Benzinga
    Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
    Via Benzinga
    RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
    RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform 
    Via News Direct
    Exposures Product Safety
    RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
    RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an... 
    Via TheNewswire.com
    Exposures Product Safety
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
    From RenovoRx, Inc.
    Via Business Wire
    Catalyst Watch: RenovoRx, Inc. Stock Jumps 14% Ahead of Thursday’s Phase III TIGeR-PaC Trial Update ($RNXT)
    Via AB Newswire
    Topics Death
    Exposures Death
    Catalyst Watch: RenovoRx, Inc. Nears June 29th Data Release From Its Phase III TIGeR-PaC Trial Targeting Pancreatic Cancer ($RNXT)
    Via AB Newswire
    Topics Death
    Exposures Death
    RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
    From RenovoRx, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.